Login / Signup

Clinical Efficacy of Olaparib in IDH1/IDH2- Mutant Mesenchymal Sarcomas.

Joseph Paul EderDeborah B DoroshowKhanh T DoVicki L KeedyJeffrey S SklarPeter M GlazerRanjit BindraGeoffrey I Shapiro
Published in: JCO precision oncology (2022)
These results indicate preliminary activity of PARP inhibition in patients with IDH1/2-mutant chondrosarcoma and pulmonary epithelioid hemangioendothelioma. Further studies of PARP inhibitors alone and in combination in this patient population are warranted.
Keyphrases
  • wild type
  • low grade
  • dna damage
  • dna repair
  • high grade
  • pulmonary hypertension
  • stem cells
  • bone marrow
  • case report
  • case control
  • oxidative stress